Podcast - Innovations and Insights in the Palliative Care Space
Regulatory Ramblings: Episode 69 - Human Intelligence vs. Machine Judgment with Nigel Morris-Cotterill and Patrick Dransfield
CareYaya: A Revolutionary Approach to Elder Care
Innovation in Compliance: Innovative Approaches to Compliance and Training with Catherine Choe
Daily Compliance News: May 15, 2025, The Downfall in Davos Edition
Work This Way: A Labor & Employment Law Podcast | Episode 46: The 2025 Greenville SHRM Conference with Tyler Clark and Brittany Goforth of GSHRM
Early Returns Podcast - Oliver Roberts: AI and the Law, and an Education
Daily Compliance News: May 14, 2025, The Widened Whistleblower Program Edition
No Password Required: CEO of HACKERverse.ai, Disruptor of Cybersecurity Sales and Most Other Things
Navigating the Maze: eDiscovery Essentials for Employers — Hiring to Firing Podcast
Daily Compliance News: May 13, 2025, The Leaving on a Jet Plane Edition
FCPA Compliance Report: Upping Your Game in Compliance
Episode 368 — LRN Issues New Report Highlighting Growing Gap in Compliance Program Performance
Creativity and Compliance: From Compliance Enforcers to Trusted Advisors: The Path Forward
Compliance and AI: Navigating Regulatory Challenges in 2025 with Allison Lagosh
Top Healthcare Compliance Priorities for 2025
Joe Green & Monica Rodriguez Kuniyoshi on Integrating Generative AI with Your Experts - Passle CMO Series Podcast RE-RELEASE:
Innovation in Compliance: Exploring the Intersection of Compliance, Technology, and AI with Ben Sperry
Harnessing the Power of eDiscovery: The Revolution of AI and Technology in Litigation and Investigations - The Consumer Finance Podcast
CMO Series Podcast RE-RELEASE: Tracey Whyte on Getting The Most Out of AI in a Lean Marketing and BD team
Recently, Carlton Fields issued its 2025 Class Action Survey based on interviews of general counsel or senior counsel at more than 300 Fortune 1000 and other large companies across a variety of industries. The results from...more
As we ring in the new year, it is time once again to reflect on some of the most significant legal developments for drug and device companies this year. The list below is by no means exhaustive (who could forget the Rule 702...more